A Novel Therapeutic System for Malignant Glioma: Nanoformulation, Pharmacokinetic and Anti-Cancer Properties of Cell-Nano-Drug delivery
Menée in vitro, cette étude évalue l'activité antitumorale de nanoparticules chargées en paclitaxel pour le traitement des gliomes
Macrophage carriage, release, and anti-tumor activities of polymeric nanoformulated paclitaxel (PTX) were developed as a novel delivery system for malignant glioma. To achieve this goal, we synthesized PTX-loaded nanoformulations (nano-PTX), then investigated their uptake, release and toxicologic properties. Chemosensitivity was significant in U87 cells (p<0.05) at concentrations from 10-4 to 10-8 M following 72 hrs exposure to bone marrow derived macrophages (BMM)-nano-PTX in comparison to treatment with nano-PTX alone. The most significant reductions in U87 cell viability (p<0.05) were observed in the transwell cocultures containing BMM-nano-PTX. Limited toxicity to BMM was observed at the same concentrations. BMM functions were tested by analysis of microtubules and actin filaments, as the cytoarchitecture, demonstrating a similar cytoskeleton pattern before and after nano-PTX loaded into cells. This data indicate that nanoformulations of PTX facilitate cell uptake, delay toxicity, and show improved therapeutic efficacy by BMM-nano-PTX delivery. A novel anti-tumor drug nanoparticle (NP) was formulated for developing of cell-NP delivery system. NP are carried within bone-marrow-derived monocytes/macrophages (BMM) demonstrating extraordinary abilities to migrate across the BBB, infiltrate into tumor, and release the anti-tumor medicine.
http://linkinghub.elsevier.com/retrieve/pii/S1549963412000093?showall=true 2012